Where we have funded research

Since its founding in 2001, LUNGevity has funded 110 research projects at 57 institutions in 23 states focusing on early detection as well as more effective treatments of lung cancer.

New Hampshire
New Jersey
New York
North Carolina



Beckman Research Institute at the City of Hope
William Bennett
DNA Methylation Changes in Peripheral Blood Monomuclear Cells as Biomarkers of Lung Cancer

Stanford University
Viswam Nair
In-vivo and in-vitro Diagnostics to Improve Lung Cancer Care

Jane Yanagawa
The Role of Snail in the Regulation of the Invasive Phenotype in NSCLC

UCLA David Geffen School of Medicine
Steven Dubinett and Kostyantyn Krysan
Combined Protein and miRNA Profiles for the Early Detection of Lung Cancer

Lee Goodglick
In Vitro and In Vivo Characterization of Estrogen Pathway Stimulation in Human Lung Cancer

Kostyantyn Krysan
Modulation of PGE2-Dependent EGFR Inhibitor Resistance in NCSLC by E-cadherin

University of  California, Davis
Oliver Fiehn, Karen Kelly and Suzanne Miyamoto
A system biology approach to biomarkers for early detection of lung cancer

University of Southern California
Nouri Neamati
Preclinical Development of SC21 in Lung Cancer

Veterans Medical Research Foundation
Randolph Hastings
Hormonal Therapy for Non-Small Cell Carcinoma

back to top


University of Colorado Denver, AMC and DC
Wilbur Franklin, Kavita Garg and York Miller
Biomarkers to Improve Clinical Assessment of Indeterminate Lung Nodules

Meredith Tennis
Biomarkers for Targeted Lung Cancer Chemoprevention

back to top


Yale University
Lynne Regan
Development of a Novel Class of Therapeutics for Bronchioloalveolar Carcinoma

Frank J. Slack
Targeting KRAS Mutations in Lung Cancer

back to top


H. Lee Moffitt Cancer Center & Research Institute
Eric Haura
Targeting SRC and Stat3 Signaling in EGFR-Driven NSCLC

Mayo Clinic Jacksonville
Alan Fields
A Novel Small Molecule Inhibitor of Protein Kinase C Iota for the Treatment of Lung Cancer

back to top


Emory University School of Medicine
Johann Brandes
Targeting CHFR through PARP-inhibition: A novel strategy to overcome taxane resistance in adenocarcinomas of the lung

Johann Brandes
CHFR methylation as novel predictor for chemotherapy response in NSCLC

Shouwei Han
Signaling through PPARy in lung cancer: Potential therapeutic role of PPARy ligands

back to top


LOGiC (Lung Oncology Group in Chicago)
Correlative study of the effects of agents used in conjunction with targeted therapies in the treatment of lung cancer

Northwestern University
Dwight Seferos
Photo-controllable Carriers for the Rapid Delivery of Anticancer Therapies

Northwestern University Feinberg School of Medicine
Navdeep Chandel
Notch signaling regulates lung cancer

Rush University Medical Center
Jeffrey Borgia
Autoantibody-based biomarkers to aid in the early diagnosis of lung cancer

Jeffrey Borgia
Molecular signatures to predict response in neoadjuvant chemoradiation therapy of Stage III NSCLC patients

Jeffrey Borgia
Diagnostic Test Development for NSCLC-Staging of Diagnosed Lung Cancer

Jeffrey Borgia
Diagnostic Test Development for NSCLC-Early Detection of Lung Cancer

University of Chicago
Federico Innocenti
Molecular signatures of angiogenesis in NSCLC and their prognostic role

Patrick Ma
Functional expression of c-Met, its mutations and targeted therapy in lung adenocarcinoma

Ravi Salgia
Studies and Therapeutic Targeting of Heat Shock Proteins in Lung Cancer

University of Illinois at Chicago College of Medicine

Sojin Shikano
Identification of molecules regulating tumorigenic KCNK9 potassium channel

back to top


University of Kansas Medical Center
Chao Huang and Sitta Sittampalam
Developing Novel Biomarkers and Targets to Address Small Cell Lung Cancer

George Vielhauer
Novel C-terminal Hsp90I with isoform selectivity will function as selective anti-cancer agents in the treatment of lung cancers

back to top


University of Louisville JG Brown Cancer Center
John Eaton
A Broad Spectrum Lung Cancer Stem Cell Vaccine

University of Louisville School of Medicine
Carolyn Klinge
Estrogen Receptor Beta Interacting Proteins in Lung Adenocarcinoma

back to top


Johns Hopkins University School of Medicine
Edward Gabrielson
Examining LKB1 status as a biomarker for response of lung cancer in metform

Erik Tryggestad
A Probabilistic Approach to High-Dose Lung IGRT

St. Joseph Medical Center Cancer Institute
Mark Krasna
Survivorship: Improving the recognition and treatment of psychosocial distress in lung cancer patients

University of Maryland, Baltimore
Feng Jiang
Sputum markers for the early detection of lung cancer 

back to top


Boston University
Jennifer Beane
Biomarkers of Pre-malignant Disease Progression for Lung Cancer Detection

Brigham and Women's Hospital
Onkar Khullar
Prevention of Nodal Metastasis in Lung Cancer via Lymphatic Trafficking of Paclitaxel-Loaded Expansile Nanoparticles

Children's Hospital Boston
Carla Kim
Isolation and characterization of bronchioloalveolar carcinoma stem cells

Dana-Farber Cancer Institute
David Kozono
Biomarkers for NSCLC Radiosensitization by Proteasome Inhibition

Matthew Meyerson
EGFR Pathway Alterations in Human Lung Adenocarcinoma

Massachusetts General Hospital
Rebecca Heist and Anthony Iafrate
Identifying Tumor Genomic Changes in Lung Cancers

Lecia Sequist
Determining Mechanisms of Resistance to Next-generation EGFR Inhibitors

Jeffrey Settleman and Sreenath Sharma
Preventing acquired resistance to geftinib and erlotinib in NSCLC

Sreenath Sharma
Chemo-sensitizing NSCLCs to Geftinib/Iressa & Erlotinib/Tarceva

back to top


University of Michigan
Douglas Arenberg
Profiling the phenotype of tumor derived stromal fibroblasts

Venkateshwar Keshamouni
Regulation of Tumor Progression in Peroxisome Proliferator-Activated Recepto-gamma in NSCLC

Mats Ljungman
 Regulation of Myc and microRNA in small cell lung cancer

Steven Zielske
Enzyme-Prodrug Gene Therapy of Cancer using Mesenchymal Stem Cells

Wayne State University
Michael Tainsky
Autoantibody biomarkers for the detection of lung cancer

Wayne State University, Karmanos Cancer Institute
Michelle Cote
Hormonal factors and lung cancer: A potential target for therapy

back to top


Mayo Clinic
Nicholas Vlahakis
The Role of alpha9beta1 Integrin in Modulating Pulmonary Angiogenesis

Mayo Clinic Cancer Center
Dennis Wigle
Surgery versus SBRT for patients with lung cancer and limited pulmonary function

Mayo Graduate School of Medicine
Clinton Doerr
Fluorescence in Situ Hybridization for the Detection of Lung Cancer

University of Minnesota
Timothy Starr
Transposon Mutagenesis for Lung Cancer Gene Discovery

back to top


Washington University
Alexander Krupnick
The Basis for Immunological Therapy of NSCLC

Christopher Maher
Molecular Predictors of Outcome in Non-small Cell Lung Cancer

back to top

New Hampshire

Dartmouth University Medical School
David Robbins
Uncovering Molecular Markers of Hedgehog Antagonist Sensitive Lung Cancer

Dartmouth-Hitchcock Medical Center
William Petty
Targeted Combination Therapy for Lung Cancer Carcinogenesis

back to top

New Jersey

Rutgers University
Tamara Minko
Enhancement of the Efficacy of Chemotherapy for Lung Cancer by Simultaneous Suppression of Multi-drug Resistance and Antiapoptotic Cellular Defenses

back to top

New York

Albert Einstein College of Medicine
Hayley McDaid
Mechanisms of RAS and RAF-mediated regulation of cap-dependent translation in NSCLC

Columbia University
Charles Powell
Molecular Signatures of Invasiveness in Lung Adenocarcinoma

Columbia University Medical Center
Balazs Halmos
Identification of predictive biomarkers of chemoradiotherapy in lung cancer

May-Lin Wilgus
Chromosome 7q copy number and lung adenocarcinoma invasion

Memorial Sloan-Kettering Cancer Center
Prasad Adusumilli
Targeted Immunotherapy for Early Stage Lung Cancer

Alexei Bogolioubov
The Occurrence of Lung Cancer after Surgical Resection: Impact of New Staging System, Use of Adjuvant Chemotherapy and Value of Chest CT Versus Chest Radiograph

William Pao
Mutational Analysis of the Tyrosine Kinase in Lung Cancer

New York University School of Medicine
Patricia Gonzalez Santamaria
Unveiling the role of Ubiquitin Ligases in the Biology and Prognosis of Lung Cancer

Jessica Scott Donington
Functional Heterogeneity of Osteopontin Isoforms in Lung Cancer

State University of New York at Buffalo
Sai Yendamuri
MiRNA expression profiling to predict recurrence after resection of stage 1 NSCLC

Sai Yendamuri
A microRNA profile to predict recurrence after surgical resection of stage 1 non-smll cell lung cancer

SUNY Upstate Medical University
Jing An
Development of new radiosensitizers for human lung cancers

back to top

North Carolina

Duke University
Mark Onaitis
Analysis of Lung Adenocarcinoma Heterogeneity Based upon Cell-of-Origin

Duke University Medical Center
Michael Campa, James Herndon and Edward Patz
Serum Biomarkers for the Early Detection of Lung Cancer

Durham VA Medical Center Pulmonary Service
Scott Shofer
Heterogeneity of Microarray-based Lung Cancer Signature in Patiens with Lung Cancer

University of North Carolina at Chapel Hill
Pilar Blancafort
Discovery of novel artificial transcription factors regulating lung cancer cell invasion and progression

University of North Carolina at Chapel Hill, Lineberger Cancer Center
Albert Baldwin
Targeting NF-KappaB as a new treatment for lung cancer

back to top


Cleveland Clinic Foundation
Peter Mazzone
Identification and validation of exhaled breath biomarkers for the detection of early stage lung cancer

Ohio State University
Wenrui Duan
Treatment of Spontaneous NSCLC in Transgenic Mice with PRIMA-1, a Novel Anti Cancer Agent

Ohio State University Medical Center
Serge Patrick Nana-Sinkam
Circulating miRNA as a Biomarker in Lung Cancer

back to top


Lankenau Institute for Medical Research
George Prendergast
Genetic regulation and therapeutic correction of immune escape in lung cancer

Thomas Jefferson University
Michael Lisanti
Role of CAV-1 in Suppressing Lung Tumor Formation: Therapeutic Implications

University of Pennsylvania
Alexander Whitehead
Folate-related biomarkers as predictors of response to pemetrexed therapy

University of Pittsburgh Cancer Institute
Timothy Burns
Targeting KRAS-mutant NSCLC Through Inhibition of MTOR and Hsp90

back to top


University of Tennessee
Hildegard Schuller
Estrogen enhances the carcinogenic effects of the nicotine derivative NNK

Vanderbilt University
William Pao
Identifying Tumor Genomic Changes in Lung Cancers

Vanderbilt University Medical Center
David Carbone
Biomarkers for personalizing adjuvant therapy in NSCLC - increasing cures

David Carbone
Predictive blood-based markers of response to VeGF Inhibitors in NSCLC

Thao Dang
Targeting Gamma-Secretase and the Notch Pathway in Lung Cancer

Mohamed Hassanein
Developing New Non-invasive Methods for the Diagnosis of Lung Cancer

back to top


University of Texas MD Anderson Cancer Center
Lauren Byers
PARP1 as a Novel Therapeutic Target in Small Cell Lung Cancer

John Heymach
Predictive blood-based markers of response to VeGF Inhibitors in NSCLC

John Heymach
EGFR/estrogen interactions: role in bronchioloalveolar carcinoma and gender differences in the efficacy of antioangiogenic therapy

Seyed Moghaddam
Inflammation-Related Lung Cancer Prevention by Targeting the NF-kB Pathway

Ignacio Wistuba
Biomarkers for personalizing adjuvant therapy in NSCLC - increasing cures

Ignacio Wistuba
Identification of biomarkers for the detection of SCLC 

UT Southwestern Medical Center
John Minna
Biomarkers for personalizing adjuvant therapy in NSCLC - increasing cures

back to top


University of Virginia
George Verghese
Regulation of NSCLC Invasion by Membrane Serine Proteinases and Antiproteinases


Fred Hutchinson Cancer Research Center
Gary Goodman, Samir Hanash and Christopher Li
Blood Tests for the Early Detection of Lung Cancer

University of Washington School of Medicine
Christopher Slatore
The Association between Incident Lung Cancer and Hormone Replacement Therapy in a Large Cohort

back to top